Mediscience Technology Corporation (MDSC-OTC: BB)
Interview with: Michael Engelhart, President and COO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their diagnostic medical devices that detect cancer and pre-cancer using light induced native tissue fluorescence spectroscopy (the "Technology") to distinguish between malignant and normal or benign tissue.

Cover Story

CEOCFO Current Issue

Cover Story Archives

Private Equity Review

CEOCFO Interview Index

Future Features

Analyst Interviews

Corporate Financials

Contact & Ordering

This is a printer friendly page!

Mediscience Technology’s Molecular Optical Biopsy through fluorescence imaging provides the ability to detect cancer and pre-cancer at a molecular level and gives the Company a leading advantage on the competition



Healthcare
Medical Equipment and Supplies
(MDSC-OTC: BB)

Mediscience Technology Corporation




Michael Engelhart
President and COO

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
June 2, 2005

To order the complete June 2, 2005 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!
You will be emailed your Current Issue and an invoice for Credit Card payment!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

”We have developed a non-invasive medical device with no need to remove tissues, no toxic dyes that delivers real-time results at point of care in less than one minute. Our technology is sensitive to structural and molecular changes enabling the detection of cancerous and pre-cancerous lesions prior to visual indication of tumor.  We have accuracy of + 90% using pathology as the gold standard and can integrate into existing diagnostic instruments.” - Michael Engelhart

Newsflash!

To view Releases highlight & left click on the company name!